- Trial phase
- Approved
- Time to market
- Already approved and launched (FDA approval received October 20, 2026). The product is commercially available in the U.S. market.
- Why 3/10
- Convenia RTU was already approved by the FDA on October 20, 2026, so the binary catalyst has passed. There is no scheduled upcoming regulatory decision or pivotal readout for this product in the next 12 months. As an approved line extension within a large, diversified animal health company, it scores a 3.
Convenia RTU was approved by the FDA on October 20, 2026, so the binary catalyst has passed. The next thing to watch is how quickly the product gains traction in the veterinary market and whether it helps stabilize Zoetis's dermatology portfolio, which declined 16% in Q3 2026 due to generic competition on the original Convenia and other pressures. Adoption metrics may be discussed on the Q4 2026 earnings call.
Price Chart
Executive Summary
Convenia RTU for Dogs (cefovecin injectable suspension) is a ready-to-use, higher-concentration formulation of Zoetis's existing Convenia antibiotic, approved by the FDA on October 20, 2026. It provides up to 14 days of treatment for bacterial skin infections in dogs with a single veterinarian-administered injection. The RTU formulation reduces injection volume compared to the original Convenia (approved in 2008), making it more practical for medium and large dogs, and eliminates the reconstitution step. For Zoetis, a $34B diversified animal health company, this is a modest line extension that helps defend against generic competition pressuring the original Convenia franchise. The binary catalyst (FDA approval) has already passed, and the product is one of many in Zoetis's broad portfolio.
How It Works
Convenia RTU is a long-acting injectable antibiotic (a cephalosporin) for dogs. A single shot given by a veterinarian provides up to 14 days of treatment for bacterial skin infections. It kills bacteria by disrupting their cell wall formation. The 'RTU' (ready-to-use) formulation is more concentrated than the original Convenia, so veterinarians can give a smaller injection volume, which is easier for medium and large dogs.
Trial Status
Convenia RTU was approved by the FDA on October 20, 2026 via a plasma bioequivalence pathway bridging to the safety and effectiveness data of the original Convenia (approved 2008). No new pivotal efficacy trials were required.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 earnings (early February 2027): first full quarter of Convenia RTU sales and commentary on adoption trends
- Potential international regulatory approvals (ex-U.S. markets) - no timeline disclosed
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zoetis Inc. 8-K ZTS ·Originating report